Posts by: Alice Melão

cystic fibrosis, News

Aridis Pharmaceuticals has enrolled the first healthy participant in its Phase 1/2a clinical trial to evaluate the antibacterial potential of its investigational candidate, AR-501 (gallium citrate), against chronic lung ... Read more

December 7, 2018December 7, 2018

Aridis to Start Phase 1/2a Trial for Inhalable Antibacterial Therapy AR-501 in CF Patients

cystic fibrosis, News

Aridis Pharmaceuticals is planning to launch a Phase 1/2a clinical trial in the beginning of 2019 to evaluate the potential of its investigational antibacterial compound AR-501 (gallium citrate) in ... Read more

November 27, 2018November 27, 2018

GEn1E to Explore MUC1-ED to Prevent P. Aeruginosa Infections in CF

cystic fibrosis, News

GEn1E Lifesciences has added to its development pipeline an investigational non-antibiotic, antibacterial agent for treatment of Pseudomonas aeruginosa infections in people with cystic fibrosis (CF). The company established an exclusive option ... Read more

November 19, 2018November 19, 2018

Orkambi Closer to Being Approved in Europe to Treat Children Ages 2-5 With Cystic Fibrosis

cystic fibrosis, News

The European Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of Orkambi (lumacaftor/ivacaftor) as a treatment for children ages 2-5 with cystic fibrosis (CF) due to F508del mutations, ... Read more

November 16, 2018November 16, 2018

New Test of Mucus Properties May Help with Coughing and Airway Clearance in CF

cystic fibrosis, News

A new test was able to assess various properties of the mucus that accumulates in the lungs of people with cystic fibrosis and other pulmonary diseases, and may help ... Read more

November 9, 2018November 9, 2018

Majority of CF Patients in Small Study Treated with Antibiotics at Levels Too Low to Fight Lung Infections

cystic fibrosis, News

Ten of 19 cystic fibrosis (CF) patients given antibiotics to manage pulmonary exacerbations did not achieve high enough blood concentrations of the antibiotic to sustain a therapeutic effect, results ... Read more

October 26, 2018October 26, 2018

#NACFC2018 – Preclinical Study Data Demonstrate Lenabasum’s Potential to Prevent Inflammatory Signals in CF

cystic fibrosis, News

Treatment with lenabasum can effectively prevent inflammation and induce pro-resolving signals in airway immune cells from patients with cystic fibrosis (CF), results from a preclinical study show. Lenabasum’s more ... Read more

October 25, 2018October 25, 2018

#NACFC2018 — Vertex Presents Latest Clinical Data on CFTR Modulators

cystic fibrosis, News

Vertex Pharmaceuticals’ VX-659 or VX-445 in combination with Kalydeco (ivacaftor) and tezacaftor (VX-661) can improve the lung function of patients with cystic fibrosis (CF) with one or two copies ... Read more

October 24, 2018October 24, 2018

PTI-808 and PTI-801 Combo Improves Lung Function in CF Patients, Phase 1 Data Show

cystic fibrosis, News

Treatment with a combo of Proteostasis Therapeutics’ investigational CFTR modulator therapies — PTI-808, a potentiator, plus PTI-801, a corrector — can promote significant improvements in lung function and reduction of sweat ... Read more

October 22, 2018October 22, 2018

FDA Approves AzurRx Biopharma Request to Test MS1819-SD in CF Patients with EPI

cystic fibrosis, News

AzurRx BioPharma is planning a multi-center Phase 2 trial to be conducted in the United States and Europe to evaluate its lead candidate MS1819-SD as a treatment for patients ... Read more

Posts by: Alice Melão

Alice Melão

Aridis Enrolling CF Patients to Test AR-501 in Chronic Lung Infections

Aridis to Start Phase 1/2a Trial for Inhalable Antibacterial Therapy AR-501 in CF Patients

GEn1E to Explore MUC1-ED to Prevent P. Aeruginosa Infections in CF

Orkambi Closer to Being Approved in Europe to Treat Children Ages 2-5 With Cystic Fibrosis

New Test of Mucus Properties May Help with Coughing and Airway Clearance in CF

Majority of CF Patients in Small Study Treated with Antibiotics at Levels Too Low to Fight Lung Infections

#NACFC2018 – Preclinical Study Data Demonstrate Lenabasum’s Potential to Prevent Inflammatory Signals in CF

#NACFC2018 — Vertex Presents Latest Clinical Data on CFTR Modulators

PTI-808 and PTI-801 Combo Improves Lung Function in CF Patients, Phase 1 Data Show

FDA Approves AzurRx Biopharma Request to Test MS1819-SD in CF Patients with EPI

Pin It on Pinterest